Based on 1 Wall Street analysts offering 12 month price targets for Towa Pharmaceutical Co in the last 3 months. The average price target is ¥3,199.31 with a high forecast of ¥3,200.00 and a low forecast of ¥3,200.00. The average price target represents a -1.71% change from the last price of ¥3,255.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2305":"¥2,305","3200":"¥3,200","2528.75":"¥2,528.8","2752.5":"¥2,752.5","2976.25":"¥2,976.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3199.998701023168,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥3.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3199.31214252,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥3.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3199.998701023168,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥3.20K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2305,2528.75,2752.5,2976.25,3200],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2819,2848.3075923863976,2877.615184772795,2906.9227771591927,2936.2303695455903,2965.537961931988,2994.8455543183854,3024.1531467047826,3053.46073909118,3082.7683314775777,3112.0759238639753,3141.383516250373,3170.6911086367704,{"y":3199.998701023168,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2819,2848.2547801938463,2877.5095603876925,2906.7643405815384,2936.0191207753846,2965.273900969231,2994.528681163077,3023.783461356923,3053.0382415507693,3082.2930217446155,3111.547801938462,3140.8025821323076,3170.057362326154,{"y":3199.31214252,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2819,2848.3075923863976,2877.615184772795,2906.9227771591927,2936.2303695455903,2965.537961931988,2994.8455543183854,3024.1531467047826,3053.46073909118,3082.7683314775777,3112.0759238639753,3141.383516250373,3170.6911086367704,{"y":3199.998701023168,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2306.095,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2568.865,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2697.308,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2802.832,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2773.12,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2862.256,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2926.632,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2852.352,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2876.121,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3070,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3085,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2820,"date":1732233600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2819,"date":1733443200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥3,200

Average Price Target¥3,199

Lowest Price Target¥3,200

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

Nomura

xxxxxxxxxxxxx

Reiterated

11/18/24

xxxxxxxxxxxxx

4553 Analyst Recommendation Trends

Rating

Sep 21

Nov 21

Nov 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4553 has received 0 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 4553 average Analyst price target in the past 3 months is ¥3,199.31.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

4553 Financial Forecast

4553 Earnings Forecast

Next quarter’s earnings estimate for 4553 is ¥57.66 with a range of ¥57.66 to ¥57.66. The previous quarter’s EPS was ¥21.53. 4553 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.87% of the time in the same period. In the last calendar year 4553 has Outperformed its overall industry.

4553 Sales Forecast

Next quarter’s sales forecast for 4553 is ¥68.96B with a range of ¥66.90B to ¥71.01B. The previous quarter’s sales results were ¥60.84B. 4553 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 48.64% of the time in the same period. In the last calendar year 4553 has Outperformed its overall industry.

4553 Stock Forecast FAQ

What is JP:4553’s average 12-month price target, according to analysts?

Based on analyst ratings, Towa Pharmaceutical Co Ltd’s 12-month average price target is ¥3,199.31.

What is JP:4553’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for JP:4553, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Towa Pharmaceutical Co Ltd a Buy, Sell or Hold?

Towa Pharmaceutical Co Ltd has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Towa Pharmaceutical Co Ltd’s share price target?

The average share price target for Towa Pharmaceutical Co Ltd is ¥3,199.31. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥3,200.00 ,and the lowest forecast is ¥3,200.00. The average share price target represents -1.71% Decrease from the current price of ¥3,255.

What do analysts say about Towa Pharmaceutical Co Ltd?

Towa Pharmaceutical Co Ltd’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Towa Pharmaceutical Co Ltd?

To buy shares of JP:4553, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Towa Pharmaceutical Co (4553) Stock Forecast & Price Target

4553 Analyst Ratings

4553 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​